Salleh Syaza, Thyagarajan Anita, Sahu Ravi P
Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, USA.
J Cancer Metastasis Treat. 2020;6. doi: 10.20517/2394-4722.2020.70. Epub 2020 Sep 17.
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most common cause of cancer-related deaths in the United States. It has a poor prognosis and remains a difficulty to treat malignancy. Over the past several decades, significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment. In recent years, the measurement of serum carbohydrate antigen 19-9 (CA 19-9) has become one of the most validated and extensively used tumour biomarkers for PDAC. In particular, serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment. However, despite its clinical relevance, the implications on diagnosis or accurately predicting tumour resectability, and monitoring disease symptoms in PDAC patients remains limited. This current review highlights the recent updates on the applicability of CA 19-9, its exploitation, and challenges in predicting the treatment efficacy and responses in PDAC patients.
胰腺导管腺癌（PDAC）目前是美国癌症相关死亡的第四大常见原因。其预后较差，仍然是一种难以治疗的恶性肿瘤。在过去几十年中，人们付出了巨大努力来开发新方法，以提高PDAC治疗方案的疗效。近年来，血清糖类抗原19-9（CA 19-9）的检测已成为PDAC最有效且应用最广泛的肿瘤生物标志物之一。特别是，血清CA 19-9水平已被作为一种有效的工具来预测疾病进展迹象或治疗反应。然而，尽管其具有临床相关性，但在PDAC患者的诊断、准确预测肿瘤可切除性以及监测疾病症状方面的意义仍然有限。本综述重点介绍了CA 19-9在预测PDAC患者治疗疗效和反应方面的适用性、应用情况及挑战的最新进展。
